FDA approves ultra-rapid lispro for use in pumps
medwireNews: Ultra-rapid lispro may now be used in insulin pumps by people with type 1 diabetes in the USA following FDA approval.
This decision in based on the results of the PRONTO-PUMP-2 trial, in which pump users had significantly lower postprandial glucose levels with ultra-rapid lispro versus lispro, and spent significantly less time in hypoglycemia overall.
The alterations to the medication label also include the warning that insulin pump or infusion set malfunction can lead rapidly to ketoacidosis.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group